Semaglutide is well tolerated with no hazard of hypoglycaemia in monotherapy but suffers from gastrointestinal adverse results. A large population influenced with COVID-19 an infection have been diabetic; hence use of semaglutide in diabetes as well as CV individuals could well be very much supportive in retaining health care process https://jaredcoyju.tkzblog.com/31720838/jq-1-role-in-gene-regulation-no-further-a-mystery